Apr 17, 2024 4:08pm EDT DiaMedica Therapeutics Announces First Patient Dosed in Relaunch of its Pivotal Phase 2/3 ReMEDy2 Trial of DM199 for the Treatment of Acute Ischemic Stroke
Mar 19, 2024 4:15pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2023 Financial Results
Jan 29, 2024 4:13pm EST DiaMedica Therapeutics Announces Poster Presentation at International Stroke Conference
Jan 22, 2024 8:23am EST DiaMedica Therapeutics Appoints Dr. Lorianne Masuoka as Chief Medical Officer
Nov 13, 2023 4:28pm EST DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial Results
Nov 09, 2023 8:25am EST DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023
Nov 06, 2023 8:23am EST DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023
Sep 12, 2023 8:13am EDT DiaMedica Therapeutics Announces the Appointment of Ambarish Shah, Ph.D. as Chief Technology Officer
Sep 06, 2023 8:35am EDT DiaMedica Therapeutics to Participate at Lake Street’s 7th Annual Best Ideas Growth Conference
Aug 14, 2023 4:13pm EDT DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2023 Financial Results